secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001048477-25-000101
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin expects $221M IPR&D charge from Inozyme acquisition, ~$1.10 EPS hit in Q3 2025
--------------------------------------------------------------------------------

- Acquired IPR&D charge of ~$221M pre-tax from July 1 Inozyme Pharma acquisition.
- Charge reduces both GAAP and Non-GAAP diluted EPS by approximately $1.10 for Q3 2025.
- Q3 2025 results not finalized; actual results may differ from preliminary estimates.
- BioMarin does not forecast IPR&D charges due to uncertainty of timing and magnitude.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000101/0001048477-25-000101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000101/bmrn-20251007.htm
  HTML page:      https://secwatch.observer/filing/0001048477-25-000101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer